Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the Community and in Europe unless they are covered by favourable rules that provide for sufficient protection to encourage such research.
Recital 3, Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009…
The 10 that are cited most themselves, of 13.
Judgment of the Court (Grand Chamber) of 25 July 2018. Teva UK Ltd and Others v Gilead Sciences Inc.Decision
Recitals 3 to 5, 7, 9 and 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [Union] and in Europe unless they are …
25 Jul 2018 · 62017CJ0121
Judgment of the Court (Fourth Chamber) of 21 March 2019. Abraxis Bioscience LLC v Comptroller General of Patents.Decision
Recitals 3 to 5 and 7 to 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [European Union] and in Europe unless they …
21 Mar 2019 · 62017CJ0443
Judgment of the Court (Grand Chamber) of 9 July 2020. Santen SAS v Directeur général de l’Institut national de la propriété industrielle.Decision
Recitals 3, 4 and 7 to 10 of Regulation No 469/2009 state: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the Community and in Europe unless they are covered by …
9 Jul 2020 · 62018CJ0673
Opinion of Advocate General Saugmandsgaard Øe delivered on 13 December 2018. Abraxis Bioscience LLC v Comptroller General of Patents.Decision
According to recitals 3, 4, 5 and 9 of Regulation No 469/2009, the SPC regime has the purpose of compensating for the lack of protection conferred by a patent with respect to covering the investment put into research concerning new …
13 Dec 2018 · 62017CC0443
Judgment of the Court (Fourth Chamber) of 30 April 2020. Royalty Pharma Collection Trust v Deutsches Patent- und Markenamt.Decision
Recitals 3 to 5, 7, 9 and 10 of Regulation No 469/2009 state as follows: Medicinal products, especially those that are the result of long, costly research, will not continue to be developed in the [European Union] and in Europe unless they …
30 Apr 2020 · 62017CJ0650
Judgment of the Court (Eighth Chamber) of 6 October 2015. Seattle Genetics Inc. v Österreichisches Patentamt.Decision
It should be noted in that regard that the fundamental objective of Regulation No 469/2009, as mentioned, inter alia, in recitals 3 to 5 and 8 and 9 in the preamble thereto, is to re-establish a sufficient period of effective protection of …
6 Oct 2015 · 62014CJ0471
Opinion of Advocate General Pitruzzella delivered on 23 January 2020. Santen SAS v Directeur général de l’Institut national de la propriété Decision
Second, Regulation No 469/2009 seeks to encourage pharmaceutical research by providing for protection to supplement that conferred by the patent, the effective duration of which is reduced because of the time required to obtain an MA …
23 Jan 2020 · 62018CC0673
Opinion of Advocate General Jääskinen delivered on 10 September 2015. Seattle Genetics Inc. v Österreichisches Patentamt.Decision
In so far as concerns the objectives which the provision at issue seeks to attain, it is common ground that the SPC for medicinal products introduced by Regulation No 1768/92 and codified by Regulation No 469/2009 increases the duration of …
10 Sep 2015 · 62014CC0471
Judgment of the Court (Second Chamber) of 20 December 2017. Incyte Corporation v Szellemi Tulajdon Nemzeti Hivatala.Decision
As regards the objectives pursued by Regulation No 469/2009, it should be noted, first, that the fundamental objective of Regulation No 469/2009, as mentioned, inter alia, in recitals 3 to 5 and 8 and 9 of that regulation, is to …
20 Dec 2017 · 62016CJ0492
Judgment of the Court (Third Chamber) of 19 December 2024. Teva BV and Teva Finland Oy v Merck Sharp & Dohme LLC and Merck Sharp & Dohme LLCDecision
Recitals 3 to 5, 7, 9 and 10 of Regulation No 469/2009 state: Medicinal products, especially those that are the result of long, costly research will not continue to be developed in the [European] Community and in Europe unless they are …
19 Dec 2024 · 62022CJ0119